A wide variety of non-steroidal anti-inflammatory drugs is now available for use in the treatment of chronic arthropathies. It is useful to compare the efficacy of a new compound with a well established therapy. In the present study, diflunisal, a new aspirin derivative, has been assessed against acetylsalicylic acid.
Pharmacology
Diflunisal, or difluoro-phenylsalicylic acid, has been shown to be superior to placebo in the treatment of pain (de Vroey, 1978; Honig, 1978; Wes, 1978) and to possess both analgesic (van Winzum and Rodda, 1977; Barrau, 1978; de Vroey, 1978; Honig, 1978; Wes, 1978) and anti-inflammatory properties (Majerus and Stanford, 1977; Stone et al., 1977) . It is well absorbed from the gastrointestinal tract, and most of it is bound in its intact form to plasma protein. The peak plasma levels occur approximately 2 hours after oral administration of 50 mg and 500 mg of the drug. The half-life of the 500 mg dose is about 10 hours. The presence of food in the stomach does not significantly delay absorption. 80-85 % of 500 mg dose of diflunisal is eliminated in the urine in the form of glucoronide metabolites. A small proportion of metabolite appear in the faeces. In animal experiments no interaction was observed between diflunisal and bishydroxycoumarin in the prothrombin test nor with tolbutamide in the glucose tolerance test.
Patients and methods
Sixty patients between the ages of 35 and 75 years were admitted to the trial. Twelve were male and 48 were female. Twenty-four patients suffered from osteoarthrosis of the hip and 36 from osteoarthrosis of the knee. The obligatory criteria for admission to the study were local pain aggravated by movement and relieved by rest, limitation of movement in the affectedjoint, and characteristic radiological changes. The additional criteria considered were night pain and the presence of inactivity stiffness.
Patients with a history of gastrointestinal disease (including definite peptic ulceration within the last 2 years or haemorrhage at any time), renal and cardiovascular disease, other joint diseases (such as rheumatoid arthritis), serious systemic illnesses such as diabetes mellitus, active tuberculosis, and marrow depression, and women of child-bearing potential were excluded.
Patients All anti-inflammatory drugs were withdrawn during the 7-day pretreatment period and not allowed for the duration of the study. Physiotherapy was not allowed either.
A full medical examination, electrocardiogram, and examination of the eyes by an ophthalmologist were performed before the patients were admitted to the study and at the end of the 12-week period. Clinical assessment and laboratory tests, which included full blood count, blood urea, serum urate, liver function tests, and examination of urine, were carried out weekly in the initial stages of the trial and then at monthly intervals.
CLINICAL ASSESSMENT
Weight bearing pain, night pain, and pain suffered during performance of a specific functional activity such as getting in and out of bed, getting up from a chair, walking a stated distance, or climbing stairs were graded by the patients on a scale ranging from 0=none to 4=very severe. Inactivity stiffness was measured in minutes. Patients were also asked to evaluate their overall response to treatment, and the investigator to assess the therapeutic effect, again using the 0-4 scale. The degree of flexion of the knee in osteoarthrosis of the knee and the intramalleolar distance in osteoarthrosis of the hip were used by the investigator in evaluation of the limitation of movement. At each visit inquiry was made as to the appearance of new symptoms that could have been attributed to the drugs used in the trial.
Results
The groups were well matched immediately prior to entry as regards the degree of weight bearing pain, night pain, and pain suffered during a specific functional activity ( (Fisher's exact test) .
The patients' overall opinion of response and the investigator's assessment of therapeutic effect at the end of the 12-week period did not differ significantly between the 2 groups as shown in Table 3 . In patients taking diflunisal the side effects which resulted in withdrawal were indigestion (1), diarrhoea (1), constipation (1), and hallucinations (1). The patient who developed hallucinations had been on concomitant nitrazepam therapy. Symptoms were severe and disturbing, but subsided completely within 24 hours of discontinuing the diflunisal. It is interesting to note that another patient who had been taking nitrazepam simultaneously with diflunisal developed lethargy and drowsiness. This lasted a couple of days but improved spontaneously without alteration to therapy.
The side effects in the diflunisal group, both in patients who completed the trial and in those who had to be withdrawn, were predominantly gastrointestinal, namely, indigestion (5) (although only 1 was withdrawn from the trial for this reason), nausea (2), flatulence (1), diarrhoea (1), and constipation (1). In 1 patient the platelet count dropped to 90 000 as recorded at week 12. A week later the count was still low at 92 000, and the drug was discontinued. However, full recovery followed within 2 weeks. There was no change in any other laboratory measured parameters except for a significant fall in serum uric acid. This confirmed the original findings of Tempero et al. (1976) (Table 5) .
Similarly in the ASA group the side effects were also mainly gastrointestinal, namely, indigestion (8), though only 2 were withdrawn from the trial because of this, nausea (5), diarrhoea (2), constipation (1), rash on face (1), and ankle swelling (1). In 1 patient there was a rise in blood urea and AST. Other adverse laboratory findings were raised serum uric acid in 1 patient and increased excretion of white blood cells in the urine of another.
Discussion
Acetylsalicylic acid was known as a herbal remedy to Table 4 Numbers ofpatients withdrawn during the study and incidence ofadverse reactions 
P>0-1 Adverse reactions(%)
13 (42) 21 (72) 0.05<P<0-1 (lab. and side effects) This trial showed that diflunisal is a useful drug in the treatment of osteoarthrosis of the hip and knee. The incidence of side effects is acceptable and twice daily dosage is a definite advantage (Wright and Hopkins, 1976 
